In contrast, a phase 2 study of continuous single-agent ibrutinib in previously untreated CLL patients (n = 34) with TP53 disruption showed the 6-year PFS was 61%, and the 6-year OS was 79% [30]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.